FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321838878> ?p ?o ?g. }

• W2321838878 endingPage "1340" @default.
• W2321838878 startingPage "1331" @default.
• W2321838878 abstract "To assess the impact of HIV-1 protease and reverse transcriptase (RT) mutations, and pharmacokinetic parameters on virological responses to nelfinavir (NFV)-containing highly active antiretroviral therapy.Naive or antiretroviral-experienced HIV-1-infected subjects were included in a non-randomized, observational cohort study and received two nucleoside RT inhibitors + NFV (750 mg three times per day or 1250 mg twice per day). Virologic success was defined as a virus load < 50 copies/ml for > 6 months.RT and protease genes were sequenced at baseline and at the time of virological failure. Plasma NFV trough concentration (Cmin), maximum concentration (Cmax), and AUC0-tau at steady-state were subjected to population pharmacokinetic analysis.Patients (n = 154) enrolled between November 1998 and February 2000 started a twice per day (n = 84) or three times per day (n = 70) NFV-based regimen as first- (n = 48) or second-line therapy when protease inhibitor-naive (n = 64) or -experienced (n = 42). Median follow-up duration was 16 months. Virologic failure occurred in 88 patients. No significant differences were observed between twice per day and three times per day regimens. According to multivariate analysis, NFV Cmin and Cmax, CD4 cell count, number of baseline RT + protease gene mutations, D67N, M184V, T215F/Y in RT, and M36I in protease, were independent factors that were significantly predictive of failure. At failure, L10I, D30N, M36I, V77I, N88S/D or L90M protease mutations had emerged since baseline. Pharmacokinetic parameters were similar in patients with or without emergence of these neo-mutations. The more discriminating NFV Cmin efficacy-threshold was estimated to be 1 mg/l.Our data confirm the association among individual pharmacokinetic parameters, genotype pattern and virological response to NFV-containing regimens." @default.
• W2321838878 created "2016-06-24" @default.
• W2321838878 creator A5012034145 @default.
• W2321838878 creator A5026504867 @default.
• W2321838878 creator A5043340550 @default.
• W2321838878 creator A5046722542 @default.
• W2321838878 creator A5055073602 @default.
• W2321838878 creator A5055378350 @default.
• W2321838878 creator A5065304753 @default.
• W2321838878 creator A5075692951 @default.
• W2321838878 creator A5086197485 @default.
• W2321838878 creator A5086527016 @default.
• W2321838878 date "2002-07-01" @default.
• W2321838878 modified "2023-10-11" @default.
• W2321838878 title "Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study)" @default.
• W2321838878 cites W1492488790 @default.
• W2321838878 cites W1997844736 @default.
• W2321838878 cites W2008847285 @default.
• W2321838878 cites W2013417313 @default.
• W2321838878 cites W2014842368 @default.
• W2321838878 cites W2025152688 @default.
• W2321838878 cites W2037036212 @default.
• W2321838878 cites W2040600082 @default.
• W2321838878 cites W2068781101 @default.
• W2321838878 cites W2092778568 @default.
• W2321838878 cites W2095709318 @default.
• W2321838878 cites W2099697190 @default.
• W2321838878 cites W2110280683 @default.
• W2321838878 cites W2114549408 @default.
• W2321838878 cites W2118379411 @default.
• W2321838878 cites W2148928395 @default.
• W2321838878 cites W2149129111 @default.
• W2321838878 cites W2160893224 @default.
• W2321838878 cites W2165770193 @default.
• W2321838878 cites W2168459018 @default.
• W2321838878 cites W2323691596 @default.
• W2321838878 cites W2323801285 @default.
• W2321838878 cites W2330848975 @default.
• W2321838878 cites W2335293609 @default.
• W2321838878 doi "https://doi.org/10.1097/00002030-200207050-00004" @default.
• W2321838878 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12131209" @default.
• W2321838878 hasPublicationYear "2002" @default.
• W2321838878 type Work @default.
• W2321838878 sameAs 2321838878 @default.
• W2321838878 citedByCount "60" @default.
• W2321838878 countsByYear W23218388782012 @default.
• W2321838878 countsByYear W23218388782014 @default.
• W2321838878 countsByYear W23218388782017 @default.
• W2321838878 countsByYear W23218388782020 @default.
• W2321838878 countsByYear W23218388782021 @default.
• W2321838878 crossrefType "journal-article" @default.
• W2321838878 hasAuthorship W2321838878A5012034145 @default.
• W2321838878 hasAuthorship W2321838878A5026504867 @default.
• W2321838878 hasAuthorship W2321838878A5043340550 @default.
• W2321838878 hasAuthorship W2321838878A5046722542 @default.
• W2321838878 hasAuthorship W2321838878A5055073602 @default.
• W2321838878 hasAuthorship W2321838878A5055378350 @default.
• W2321838878 hasAuthorship W2321838878A5065304753 @default.
• W2321838878 hasAuthorship W2321838878A5075692951 @default.
• W2321838878 hasAuthorship W2321838878A5086197485 @default.
• W2321838878 hasAuthorship W2321838878A5086527016 @default.
• W2321838878 hasBestOaLocation W23218388781 @default.
• W2321838878 hasConcept C104317684 @default.
• W2321838878 hasConcept C112705442 @default.
• W2321838878 hasConcept C126322002 @default.
• W2321838878 hasConcept C142462285 @default.
• W2321838878 hasConcept C156719811 @default.
• W2321838878 hasConcept C159047783 @default.
• W2321838878 hasConcept C181199279 @default.
• W2321838878 hasConcept C182707283 @default.
• W2321838878 hasConcept C203014093 @default.
• W2321838878 hasConcept C22979827 @default.
• W2321838878 hasConcept C2522874641 @default.
• W2321838878 hasConcept C2776714187 @default.
• W2321838878 hasConcept C2778335254 @default.
• W2321838878 hasConcept C2781143361 @default.
• W2321838878 hasConcept C2781160516 @default.
• W2321838878 hasConcept C2781413609 @default.
• W2321838878 hasConcept C2908647359 @default.
• W2321838878 hasConcept C2993143319 @default.
• W2321838878 hasConcept C49105822 @default.
• W2321838878 hasConcept C54355233 @default.
• W2321838878 hasConcept C55493867 @default.
• W2321838878 hasConcept C71924100 @default.
• W2321838878 hasConcept C86803240 @default.
• W2321838878 hasConcept C98274493 @default.
• W2321838878 hasConcept C99454951 @default.
• W2321838878 hasConceptScore W2321838878C104317684 @default.
• W2321838878 hasConceptScore W2321838878C112705442 @default.
• W2321838878 hasConceptScore W2321838878C126322002 @default.
• W2321838878 hasConceptScore W2321838878C142462285 @default.
• W2321838878 hasConceptScore W2321838878C156719811 @default.
• W2321838878 hasConceptScore W2321838878C159047783 @default.
• W2321838878 hasConceptScore W2321838878C181199279 @default.
• W2321838878 hasConceptScore W2321838878C182707283 @default.
• W2321838878 hasConceptScore W2321838878C203014093 @default.
• W2321838878 hasConceptScore W2321838878C22979827 @default.
• W2321838878 hasConceptScore W2321838878C2522874641 @default.

• next